Katherine DeLaGarza

Katherine DeLaGarza asked about the potential launch trajectory in Europe versus the U.S., inquiring if key learnings from the U.S. experience could accelerate European uptake, and for comments on the sales force needed if Soleno were to commercialize on its own in Europe.

Answer

Meredith Manning, Chief Commercial Officer, stated that the company is still evaluating the size of the field force, focusing initially on Germany and Austria. She highlighted that Europe has more concentrated centers of excellence, and strong education of treaters on patient selection has been key in the U.S. and would be important in Europe.